↓ Skip to main content

Dove Medical Press

Article Metrics

The clinical development of obinutuzumab for the treatment of follicular lymphoma

Overview of attention for article published in Cancer Management and Research, April 2017
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (61st percentile)
  • Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

patent
1 patent

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
23 Mendeley
Title
The clinical development of obinutuzumab for the treatment of follicular lymphoma
Published in
Cancer Management and Research, April 2017
DOI 10.2147/cmar.s114526
Pubmed ID
Authors

Barbara Ma, Chaitra Ujjani

Abstract

Impressive progress has been made in recent decades for advanced-stage follicular lymphoma with the availability of anti-CD20 monoclonal antibodies, initially rituximab and more recently obinutuzumab. Obinutuzumab is a unique, third-generation, fully humanized glycoengineered IgG1 type II anti-CD20 monoclonal antibody. It has been shown to have increased antitumor activity compared to rituximab in preclinical studies, including whole-blood B-cell depletion assays, xenograft models, and primate models. This has spurred on the development of obinutuzumab through Phase I/II trials as monotherapy and in combination with chemotherapeutic agents and other targeted therapies. Its efficacy compared to rituximab and in rituximab-refractory disease has led to its continued development and eventual approval for the treatment of follicular lymphoma. Here in this review, we highlight the design and development of obinutuzumab in the treatment of advanced stage grade 1-3A follicular lymphoma and its future directions.

Mendeley readers

The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 23 100%

Demographic breakdown

Readers by professional status Count As %
Other 5 22%
Researcher 4 17%
Student > Master 4 17%
Student > Ph. D. Student 3 13%
Student > Bachelor 2 9%
Other 2 9%
Unknown 3 13%
Readers by discipline Count As %
Medicine and Dentistry 9 39%
Biochemistry, Genetics and Molecular Biology 3 13%
Pharmacology, Toxicology and Pharmaceutical Science 3 13%
Materials Science 2 9%
Economics, Econometrics and Finance 1 4%
Other 2 9%
Unknown 3 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 January 2019.
All research outputs
#4,581,235
of 14,826,751 outputs
Outputs from Cancer Management and Research
#121
of 950 outputs
Outputs of similar age
#97,307
of 268,127 outputs
Outputs of similar age from Cancer Management and Research
#4
of 12 outputs
Altmetric has tracked 14,826,751 research outputs across all sources so far. This one is in the 49th percentile – i.e., 49% of other outputs scored the same or lower than it.
So far Altmetric has tracked 950 research outputs from this source. They receive a mean Attention Score of 2.2. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 268,127 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.